MCD lives on people liking what they eat and eating a lot of it. The Happy Meal is famous.
into the business model comes the new wave biologics for obesity and diabetes. the shots
that cut down the weight and the food addiction. Insurance companies are jumping on
the bandwagon. 1/3 of the people eat half the food. Increasingly, those people are...
CMG has announced a split. Makes sense to make shares more affordable but fractionals are
widely available. CMG may be fundamentally challenged by the underpinnings of the fast food
markets. that is overeating and rising prices. In the meanwhile the anti-obesity and anti-
diabetes trends are pushing hard led by the bological injectable meds from LLY, NVO...
Does look bullish. OverSold on daily, Golden pocket, KDJ Bullish.
If we go past my target or hold that level and not go down, it's full continuation of Bull for this stock.
Insulet (NASDAQ: PODD) stands as an innovative medical device company committed to enhancing the lives of individuals grappling with diabetes and related conditions through its...
The technical figure Channel Up can be found in the daily chart in the French company Sanofi S.A. (SAN.pa). Sanofi S.A. is a French multinational pharmaceutical and healthcare company. Sanofi engages in the research and development, manufacturing and marketing of pharmacological products, principally in the prescription market, but the firm also develops...
NASDAQ:PODD & NASDAQ:DXCM are leading the sectors recovery.
Both are in the Medical Products Industry for diabetes.
Insulent (PODD) normally outperforms DexCom (DXCM) during and after a correction. Then, when they are in sustained uptrends, DXCM outperforms.
For the recent correction, PODD has a -45% deep base while DXCM has a -58%.
PODD bottmed 4 weeks...
A cup and a handle if I ever saw one!
Diamyd has been reporting some great news lately: the Diamyd vaccine showing great results in clinical trials conducted in January this year , as well as getting their manufacturing plant ready for production of the vaccine!
Notice the rising trend in accumulation/distribution, following along with the price action....
Diamyd chart has repeated this descending wedge pattern, followed by breakouts, thrice during the past three months. A fourth inning is in sight, as they are getting ready to head into the phase III clinical trials (labeled "DIAGNODE-3") of their diabetes vaccine "Diamyd".
Trying to sound like I know something...overbought here as it's accelerating too quickly. I think we bounce down as some (smarter than me) take well timed profits. Still heading for $133...still long...I just think this is too fast
After some conversation with a young single mom and what she goes through to get her and her 2 yr old diabetes meds @ $13hr...f to the big pharma and f to the health care that does not cover such a life saving drug. It's not a conspiracy...it's a cultural failure to recognize how far we have come in such a short time. Some will call it profiteering...sure but it's...
Stock price has not been fully established yet. Lots of uncertainty, meaning lots of opportunity for short term fluctuations. Stock just underwent reverse split. Currently a "low floater", but with real business operations, not just some cheap pump and dump scam from china or some bitcoin stock. Its a real company with real aspirations of survival. Only...
Provisional patent numbers have arrived!! This is absolutely HUGE.
Lets also not forget we've got a conference coming Friday which will be bring many new ideas to the company.
Millionaires will be made!!!
I'm seeing some bashing of this company on a few other outlets.
I think one thing new investors into VDRM need to realize is that greatness takes time. If you bought into it at 0.06-0.07 because somebody told you it was going to run to a $1 overnight, that's all on the trader and not on the stock.
If you look at the chart, this is a very healthy company with a...
